Triazole-derivatives as blood clotting enzyme factor Xa inhibitors

US7223780B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Marc Nazare · Idstein, DE
• Volker Laux · Mainz, DE
• Armin Bauer · Pocking, DE
• Michael Wagner · Frankfurt am Main, DE

Key dates

• Filing date: May 19, 2004
• Grant date: May 29, 2007
• Expiry date: Aug 26, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of blood clotting enzyme Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically treating a patient suffering from, or subject to, a disease state associated with a cardiovascular disorder.